Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06643780
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-15
Brief Title:
RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
RANK-ligand Inhibition to Combat Sarcopenia with Underlying Osteoporosis a Randomized Double-blind Double-dummy Active-Controlled Trial
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study was to conduct a randomized double-blind double-dummy active controlled trial to determine the efficacy of denosumab in treating sarcopenia with underlying osteoporosis
Detailed Description:
Aims
1 To assess whether receptor activator of nuclear factor-kB ligand RANKL-inhibition can treat sarcopenia in osteosarcopenic patients in terms of appendicular skeletal muscle mass ASM handgrip strength and physical performance
2 To assess whether RANKL-inhibition improves quality of life and decreases falls fractures hospital admissions and mortality in osteosarcopenic patients
1 To assess whether receptor activator of nuclear factor-kB ligand RANKL-inhibition can treat sarcopenia in osteosarcopenic patients in terms of appendicular skeletal muscle mass ASM handgrip strength and physical performance
2 To assess whether RANKL-inhibition improves quality of life and decreases falls fractures hospital admissions and mortality in osteosarcopenic patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None